Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Other Operating Expenses (2019 - 2025)

Sangamo Therapeutics has reported Other Operating Expenses over the past 5 years, most recently at $13.2 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $13.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $13.2 million (up 139.72% YoY), and the annual figure for FY2025 was $13.2 million, up 139.72%.
  • Other Operating Expenses for Q4 2025 was $13.2 million at Sangamo Therapeutics, up from $1.2 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for SGMO hit a ceiling of $58.6 million in Q1 2023 and a floor of $296000.0 in Q4 2023.
  • Median Other Operating Expenses over the past 3 years was $13.2 million (2025), compared with a mean of $24.8 million.
  • Peak annual rise in Other Operating Expenses hit 92.57% in 2024, while the deepest fall reached 97.72% in 2024.
  • Sangamo Therapeutics' Other Operating Expenses stood at $296000.0 in 2023, then skyrocketed by 295.95% to $1.2 million in 2024, then skyrocketed by 1029.27% to $13.2 million in 2025.
  • The last three reported values for Other Operating Expenses were $13.2 million (Q4 2025), $1.2 million (Q2 2024), and $4.3 million (Q1 2024) per Business Quant data.